source
- MapLight's schizophrenia drug fails primary endpoint in Phase 2, sending stock down over 60%MapLight Therapeutics saw its shares tumble more than 60% after a mid‑stage trial showed that its once‑daily schizophrenia candidate did not meet the primary efficacy endpoint, even though the over…
- Sarepta appoints former AbbVie R&D chief Michael Severino as new CEO amid DMD regulatory outlookSarepta Therapeutics announced that Michael Severino, who previously led Tessera Therapeutics and served as AbbVie’s head of research and development, will become the company’s chief executive. Sev…